Key Sessions
James Wells, PhD
Attacking the Cancer Surfaceome
UCSF
Jo Viney, PhD
Engineering for Optimal Receptor Agonism
Seismic Therapeutic
Erica Ollmann Saphire, PhD
Antibodies Against Viral Threats
La Jolla Institute for Immunology
Ray Deshaies, PhD
How Multispecific Biologics are Transforming Pharmacotherapy
Amgen
Main Conference Day 1 - PT (Pacific Time, GMT-08:00)
Main Conference Day 1
- PT (Pacific Time, GMT-08:00)
7:00am - 8:00am60 mins
Keynote Presentations
Registration and Breakfast
8:00am - 8:05am5 mins
Keynote Presentations
Co-Chairs' Welcome and Opening Remarks
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
8:05am - 8:45am40 mins
Keynote Presentations
Attacking the Cancer Surfaceome
- James Wells, PhD - Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, UCSF
8:45am - 9:25am40 mins
Keynote Presentations
Engineering for Optimal Receptor Agonism
- Jo Viney, PhD - Co-Founder and CEO, Seismic Therapeutic
9:25am - 10:05am40 mins
Keynote Presentations
Antibodies Against Viral Threats
- Erica Ollmann Saphire, PhD - Professor, La Jolla Institute for Immunology
10:05am - 10:35am30 mins
Keynote Presentations
Networking Refreshment Break
10:35am - 11:15am40 mins
Keynote Presentations
How Multispecific Biologics are Transforming Pharmacotherapy
- Ray Deshaies, PhD - Distinguished Fellow, Amgen
11:15am - 11:45am30 mins
Keynote Presentations
Jim Huston Science Talent Award and Presentation: Mechanisms and Therapeutic Applications of Membrane Protein Degraders
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Jenna Guthmiller, PhD - Assistant Professor, Department of Immunology, University of Colorado Anschutz Medical Campus
- Xin Zhou, Ph.D. - Assistant Professor of Biological Chemistry & Mole, Dana-Farber & Harvard Medical School
11:45am - 12:10pm25 mins
Keynote Presentations
Keynote Panel Discussion: New Modalities and Technologies Fueling Next-generation Therapeutics
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- James Wells, PhD - Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, UCSF
- Jo Viney, PhD - Co-Founder and CEO, Seismic Therapeutic
- Ray Deshaies, PhD - Distinguished Fellow, Amgen
12:10pm - 12:15pm5 mins
Keynote Presentations
Transition to Scientific Luncheon Briefings
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 1
OptiMAL™: Mammalian Display of a Human IgG Library for Discovery of Novel Antibodies
- Richard Buick, PhD - Chief Technical Officer, Fusion Antibodies plc
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 2
Next-Generation Bispecific Antibody Manufacturing: Enhancing Productivity and Purity through GenScript’s TurboCHO Technology
- Heng Tai Liew, PhD - Senior Protein Scientist, GenScript
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 3
A Meta-Analysis of 150+ Antibody Discovery Campaigns: Various Transgenic and Hyperimmune Mice Performance on Single B Cell Screening Platforms
- Colby Souders, PhD - Chief Scientific Officer, Biopharma, Twist Bioscience
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 5
Tips and Tricks in speeding up Transient HEK293 and Transient/Stable CHO from 96 well, 24 well, 6 well, 125mL-7L Optimum Growth Flasks
- Sam Ellis - Chief Executive Officer, Thomson Instrument Company
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 6
OmniUltra™: A new in vivo platform for discovery of novel mini-proteins and structured peptides
- Yasmina Abdiche, PhD - SVP, Exploratory Research, OmniAb
1:15pm - 1:45pm30 mins
Scientific Briefing 1
Simplified and Humanized: Empowering Humanized Antibody Discovery with AbDrop™ Solution
- Lei Shi, PhD - Senior Vice President, Biointron Biological
1:15pm - 1:45pm30 mins
Scientific Briefing 3
An Integrated Pipeline From Antibody Panel to Drug Candidates
- Jeff Johnson - Senior Scientific Director of Cell Line Development and Biologics, ATUM
1:15pm - 1:45pm30 mins
Scientific Briefing 4
Empowering Next-Gen Protein Design: A Multimodal Intelligence Platform for Advanced Immunotherapy
- Christian Olsen - Vice President, Strategy - Protein Therapeutics, Luma, Dotmatics
1:15pm - 1:45pm30 mins
Scientific Briefing 5
Advancing Multi-Objective Antibody Selection Through AI-Driven Pareto Optimization
- Kemal Sonmez, PhD - Senior Applied AI Scientist, Amazon Web Services
1:45pm - 2:15pm30 mins
Scientific Briefing 1
Tackling Challenging Targets with End-to-end AI-driven Antibody Discovery Platform
- Barry Duplantis, PhD - Senior Director of Business Development, Ailux
1:45pm - 2:15pm30 mins
Scientific Briefing 2
In Vitro Assays for T Cell Engagers and Autoimmune Targets - From Bench to Data-Driven Decisions
- Rachel Wang, PhD - Associate Director (SME), CRO Services, WuXi Biologics
1:45pm - 2:15pm30 mins
Scientific Briefing 4
VHH/VH Enabled Next Generation Therapeutics Past, Present and Future
- Imran Clark, PhD - Director Business Development, Nona Biosciences
1:45pm - 2:15pm30 mins
Scientific Briefing 5
Pfast™ Protein Expression: A Rapid, Robust Solution for Accelerating Antibody Screening
- Diane Retallack, PhD - President & COO, Primrose Bio
2:25pm - 2:30pm5 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Co-Chairs' Remarks -Enhanced Efficacy Through Fc Engineering
- Stephen Beers, PhD - Professor of Immunology and Immunotherapy, University of Southampton
- Jan Terje Andersen, Ph.D. - Professor, University of Oslo and Group Leader, Oslo University Hospital
2:25pm - 2:30pm5 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Co-Chairs’ Remarks - Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
- James Wells, PhD - Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, UCSF
- Xin Zhou, Ph.D. - Assistant Professor of Biological Chemistry & Mole, Dana-Farber & Harvard Medical School
2:30pm - 3:00pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Superdimeric Antibody NK Engagers and T cell Engagers for B Cell Depletion
- Daniel Capon, PhD - Chief Scientific Officer, Hinge Bio, Inc.
2:30pm - 3:00pm30 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
To Be or Not bE3? Targeted Membrane Protein Degradation Using Heterobispecific Antibodies (SureTACs)
- Madelon Maurice - Full Professor, UMC Utrecht
3:00pm - 3:30pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Complement Activation by IgG Subclasses is Governed By Their Ability to Oligomerize Upon Antigen Binding
- Frank Beurskens, PhD - Director and Antibody Format Translation Lead, Genmab
3:00pm - 3:30pm30 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Late Breaking Presentation
3:30pm - 4:00pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Integrating Metabolic Glycoengineering with Fc Engineering for Efficient Site-specific Antibody Conjugate Production
- Jamie Spangler, PhD - Associate Professor, Johns Hopkins University
3:30pm - 3:45pm15 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Engineering LIPTACs for membrane protein degradation and enhanced drug delivery
- Fangzhu Zhao, PhD - Postdoctoral Fellow, University of California, San Francisco
3:45pm - 4:00pm15 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Targeted Degradation of Extracellular Proteins Via Induced Shedding
- Zi Yao, PhD - Postdoctoral Fellow, Wells Lab, University of California, San Francisco
4:00pm - 4:45pm45 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Networking Refreshment Break, Exhibit and Poster Viewing
4:00pm - 4:45pm45 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Networking Refreshment Break, Exhibit and Poster Viewing
4:45pm - 5:15pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Step-wise optimization of a next generation FcRn inhibitor fused to an albumin binder for improved IgG clearance
- Annelies Bogaert, PhD - Senior scientist, Argenx
4:45pm - 5:15pm30 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
MoDE™ Molecular Degraders of Extracellular Proteins
- David Spiegel, M.D, PhD - Professor of Chemistry and Pharmacology, Yale University
5:15pm - 5:45pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Scientific and Clinical Development of a Monoclonal Antibody to Prevent Malaria
- Robert Seder, MD - Chief, Cellular Immunology Section, Vaccine Research Center, NIAID, NIH
5:15pm - 5:45pm30 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
Trafficking Biology
- Steven Banik, PhD - Assistant Professor of Chemistry, Stanford University
5:45pm - 6:15pm30 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Fc Engineering to Resist Cytomegalovirus Immune Evasion and Restore NK Cell Activation Against Infected Cells
- Jennifer Maynard, PhD - ZD Bonner Professor & Associate Chair, The University of Texas at Austin
5:45pm - 6:15pm30 mins
Track 2: Novel Extracellular Protein Degraders & Beyond to Modulate Therapeutic Protein Targets
EpiTACs are Bispecific Antibodies that Degrade Extracellular Targets to Overcome Limitations of Current Antibody and ADC Therapeutics
- Shyra Gardai, Ph.D. - Chief Scientific Officer, EpiBiologics
6:15pm - 7:45pm90 mins
Track 1: Enhanced Efficacy Through Fc Engineering
Opening Night Networking Reception, Exhibits and Poster Viewing
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。